145 related articles for article (PubMed ID: 9436193)
1. Future challenges in the clinical development of thymidylate synthase inhibitor compounds.
Brandt DS; Chu E
Oncol Res; 1997; 9(8):403-10. PubMed ID: 9436193
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase inhibitors.
Touroutoglou N; Pazdur R
Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
4. Folate-based thymidylate synthase inhibitors as anticancer drugs.
Jackman AL; Calvert AH
Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside.
Chu E; Callender MA; Farrell MP; Schmitz JC
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S80-9. PubMed ID: 12819937
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.
Van Triest B; Peters GJ
Oncology; 1999 Oct; 57(3):179-94. PubMed ID: 10545786
[TBL] [Abstract][Full Text] [Related]
7. Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
Gangjee A; Jain HD; McGuire JJ; Kisliuk RL
J Med Chem; 2004 Dec; 47(27):6730-9. PubMed ID: 15615522
[TBL] [Abstract][Full Text] [Related]
8. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
Schultz RM; Patel VF; Worzalla JF; Shih C
Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579
[TBL] [Abstract][Full Text] [Related]
9. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase inhibitors.
Danenberg PV; Malli H; Swenson S
Semin Oncol; 1999 Dec; 26(6):621-31. PubMed ID: 10606255
[TBL] [Abstract][Full Text] [Related]
11. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
Rustum YM; Harstrick A; Cao S; Vanhoefer U; Yin MB; Wilke H; Seeber S
J Clin Oncol; 1997 Jan; 15(1):389-400. PubMed ID: 8996166
[TBL] [Abstract][Full Text] [Related]
13. Novel 2-amino-4-oxo-5-arylthio-substituted-pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase.
Gangjee A; Jain HD; Kisliuk RL
Bioorg Med Chem Lett; 2005 May; 15(9):2225-30. PubMed ID: 15837298
[TBL] [Abstract][Full Text] [Related]
14. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
Van Triest B; Pinedo HM; Giaccone G; Peters GJ
Ann Oncol; 2000 Apr; 11(4):385-91. PubMed ID: 10847455
[TBL] [Abstract][Full Text] [Related]
15. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
16. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
[TBL] [Abstract][Full Text] [Related]
17. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
Temmink OH; Hoogeland MF; Fukushima M; Peters GJ
Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590
[TBL] [Abstract][Full Text] [Related]
18. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
19. Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase.
Nivens MC; Felder T; Galloway AH; Pena MM; Pouliot JJ; Spencer HT
Cancer Chemother Pharmacol; 2004 Feb; 53(2):107-15. PubMed ID: 14605862
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.
Rafi I; Taylor GA; Calvete JA; Boddy AV; Balmanno K; Bailey N; Lind M; Calvert AH; Webber S; Jackson RC
Clin Cancer Res; 1995 Nov; 1(11):1275-84. PubMed ID: 9815922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]